BDF Gestion Sells 2,899 Shares of Hologic, Inc. (NASDAQ:HOLX)

BDF Gestion cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,312 shares of the medical equipment provider’s stock after selling 2,899 shares during the quarter. BDF Gestion’s holdings in Hologic were worth $1,608,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Public Sector Pension Investment Board lifted its stake in Hologic by 92.5% in the second quarter. Public Sector Pension Investment Board now owns 8,759 shares of the medical equipment provider’s stock worth $650,000 after acquiring an additional 4,208 shares during the period. Creative Planning lifted its position in shares of Hologic by 2.4% in the 2nd quarter. Creative Planning now owns 21,813 shares of the medical equipment provider’s stock worth $1,620,000 after purchasing an additional 503 shares during the period. Sunbelt Securities Inc. bought a new position in shares of Hologic during the second quarter valued at approximately $37,000. Sanctuary Advisors LLC purchased a new position in Hologic during the second quarter valued at approximately $1,212,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in Hologic in the second quarter worth approximately $100,000. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.1 %

Hologic stock opened at $72.17 on Friday. Hologic, Inc. has a 52 week low of $68.61 and a 52 week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average price of $73.49 and a 200 day moving average price of $78.11. The company has a market capitalization of $16.29 billion, a price-to-earnings ratio of 21.67, a price-to-earnings-growth ratio of 2.43 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.89 earnings per share. Sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent research reports. JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Leerink Partners cut their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Raymond James increased their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, Morgan Stanley decreased their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.